Predictors of Life Expectancy in Autopsy-Confirmed Alzheimer's Disease
- PMID: 35034898
- PMCID: PMC8966055
- DOI: 10.3233/JAD-215200
Predictors of Life Expectancy in Autopsy-Confirmed Alzheimer's Disease
Erratum in
-
Erratum to: Predictors of Life Expectancy in Autopsy-Confirmed Alzheimer's Disease.J Alzheimers Dis. 2022;90(2):929. doi: 10.3233/JAD-229015. J Alzheimers Dis. 2022. PMID: 36314232 No abstract available.
Abstract
Background: Life expectancy (LE) following Alzheimer's disease (AD) is highly variable. The literature to date is limited by smaller sample sizes and clinical diagnoses.
Objective: No study to date has evaluated predictors of AD LE in a retrospective large autopsy-confirmed sample, which was the primary objective of this study.
Methods: Participants (≥50 years old) clinically and neuropathologically diagnosed with AD were evaluated using National Alzheimer's Coordinating Center (N = 1,401) data. Analyses focused on 21 demographic, medical, neuropsychiatric, neurological, functional, and global cognitive predictors of LE at AD dementia diagnosis. These 21 predictors were evaluated in univariate analyses. Variables found to be significant were then entered into a forward multiple regression. LE was defined as months between AD diagnosis and death.
Results: Fourteen predictors were significant in univariate analyses and entered into the regression. Seven predictors explained 27% of LE variance in 764 total participants. Mini-Mental State Examination (MMSE) score was the strongest predictor of LE, followed by sex, age, race/ethnicity, neuropsychiatric symptoms, abnormal neurological exam results, and functional impairment ratings. Post-hoc analyses revealed correlations of LE were strongest with MMSE ≤12.
Conclusion: Global cognitive functioning was the strongest predictor of LE following diagnosis, and AD patients with severe impairment had the shortest LE. AD patients who are older, male, white, and have more motor symptoms, functional impairment, and neuropsychiatric symptoms were also more likely have shorter LE. While this model cannot provide individual prognoses, additional studies may focus on these variables to enhance predictions of LE in patients with AD.
Keywords: Alzheimer’s disease; autopsy-confirmed; dementia; life expectancy; mortality.
Figures
Similar articles
-
Predictors of patient self-ratings of quality of life in Alzheimer disease: cross-sectional results from the Canadian Alzheimer's Disease Quality of Life Study.Am J Geriatr Psychiatry. 2011 Oct;19(10):881-90. doi: 10.1097/JGP.0b013e3182006a67. Am J Geriatr Psychiatry. 2011. PMID: 21946804 Free PMC article.
-
Modeling the Relationships Among Late-Life Body Mass Index, Cerebrovascular Disease, and Alzheimer's Disease Neuropathology in an Autopsy Sample of 1,421 Subjects from the National Alzheimer's Coordinating Center Data Set.J Alzheimers Dis. 2017;57(3):953-968. doi: 10.3233/JAD-161205. J Alzheimers Dis. 2017. PMID: 28304301 Free PMC article.
-
Specific Neuropsychiatric Symptoms Are Associated with Faster Progression in Alzheimer's Disease: Results of the Prospective Dementia Registry (PRODEM-Austria).J Alzheimers Dis. 2020;73(1):125-133. doi: 10.3233/JAD-190662. J Alzheimers Dis. 2020. PMID: 31744004
-
Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov. Report No.: 14-05198-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov. Report No.: 14-05198-EF-1. PMID: 24354019 Free Books & Documents. Review.
-
Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Feb. Report No.: 19-05257-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Feb. Report No.: 19-05257-EF-1. PMID: 32129963 Free Books & Documents. Review.
Cited by
-
Validation of a Multivariate Prediction Model of the Clinical Progression of Alzheimer's Disease in a Community-Dwelling Multiethnic Cohort.J Alzheimers Dis. 2023;95(1):93-117. doi: 10.3233/JAD-220811. J Alzheimers Dis. 2023. PMID: 37482990 Free PMC article.
-
Development and validation of a clinical prediction tool to estimate survival in community-dwelling adults living with dementia: a protocol.BMJ Open. 2024 Nov 17;14(11):e086231. doi: 10.1136/bmjopen-2024-086231. BMJ Open. 2024. PMID: 39551579 Free PMC article.
-
A glimpse into the future: revealing the key factors for survival in cognitively impaired patients.Front Aging Neurosci. 2024 Jul 4;16:1376693. doi: 10.3389/fnagi.2024.1376693. eCollection 2024. Front Aging Neurosci. 2024. PMID: 39026993 Free PMC article.
References
-
- Alzheimer’s Association (2018) 2018 Alzheimer’s disease facts and figures. Alzheimers Dement 14, 367–429.
-
- Todd S, Barr S, Roberts M, Passmore AP (2013) Survival in dementia and predictors of mortality: A review. Int J Geriatr Psychiatry 28, 1109–1124. - PubMed
-
- Brookmeyer R, Corrada MM, Curriero FC, Kawas C (2002) Survival following a diagnosis of Alzheimer disease. Arch Neurol 59, 1764–1767. - PubMed
Publication types
MeSH terms
Grants and funding
- P30 AG066518/AG/NIA NIH HHS/United States
- P50 AG005142/AG/NIA NIH HHS/United States
- P50 AG016573/AG/NIA NIH HHS/United States
- P50 AG047266/AG/NIA NIH HHS/United States
- P30 AG010161/AG/NIA NIH HHS/United States
- P50 AG025688/AG/NIA NIH HHS/United States
- P50 AG005138/AG/NIA NIH HHS/United States
- P50 AG047366/AG/NIA NIH HHS/United States
- P30 AG028383/AG/NIA NIH HHS/United States
- P50 AG033514/AG/NIA NIH HHS/United States
- P30 AG013854/AG/NIA NIH HHS/United States
- P30 AG053760/AG/NIA NIH HHS/United States
- P30 AG072975/AG/NIA NIH HHS/United States
- P30 AG010124/AG/NIA NIH HHS/United States
- P50 AG023501/AG/NIA NIH HHS/United States
- P50 AG005131/AG/NIA NIH HHS/United States
- P30 AG010133/AG/NIA NIH HHS/United States
- P50 AG016574/AG/NIA NIH HHS/United States
- P50 AG005146/AG/NIA NIH HHS/United States
- U24 AG072122/AG/NIA NIH HHS/United States
- P30 AG035982/AG/NIA NIH HHS/United States
- P50 AG008702/AG/NIA NIH HHS/United States
- U01 AG016976/AG/NIA NIH HHS/United States
- P30 AG008051/AG/NIA NIH HHS/United States
- P50 AG005681/AG/NIA NIH HHS/United States
- P30 AG013846/AG/NIA NIH HHS/United States
- P50 AG047270/AG/NIA NIH HHS/United States
- P50 AG005136/AG/NIA NIH HHS/United States
- P30 AG049638/AG/NIA NIH HHS/United States
- P30 AG012300/AG/NIA NIH HHS/United States
- P50 AG005134/AG/NIA NIH HHS/United States
- P30 AG008017/AG/NIA NIH HHS/United States
- P50 AG005133/AG/NIA NIH HHS/United States
- P30 AG066509/AG/NIA NIH HHS/United States
- P30 AG062715/AG/NIA NIH HHS/United States
- P30 AG010129/AG/NIA NIH HHS/United States
- P30 AG019610/AG/NIA NIH HHS/United States
- P30 AG072947/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical